NCT03165435 - A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis | Biotech Hunter

Timeline

Start Date

July 31, 2018

Primary Completion Date

October 1, 2019

Study Completion Date

December 31, 2019

Conditions

Myasthenia Gravis, Generalized

Interventions

BIOLOGICAL

CV-MG01

3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.

BIOLOGICAL

Placebo

3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.

Trial Locations (1)

2650

University Hospital, Antwerp, Edegem